Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Depreciation (2022 - 2025)

Historic Accumulated Depreciation for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $4.4 million.

  • Taysha Gene Therapies' Accumulated Depreciation rose 1203.37% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 1203.37%. This contributed to the annual value of $3.6 million for FY2024, which is 2030.88% up from last year.
  • Taysha Gene Therapies' Accumulated Depreciation amounted to $4.4 million in Q3 2025, which was up 1203.37% from $4.1 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Accumulated Depreciation high stood at $4.4 million for Q3 2025, and its period low was $754000.0 during Q1 2022.
  • Its 4-year average for Accumulated Depreciation is $2.8 million, with a median of $3.0 million in 2023.
  • As far as peak fluctuations go, Taysha Gene Therapies' Accumulated Depreciation skyrocketed by 16167.11% in 2023, and later surged by 1203.37% in 2025.
  • Taysha Gene Therapies' Accumulated Depreciation (Quarter) stood at $1.6 million in 2022, then soared by 81.43% to $3.0 million in 2023, then increased by 20.31% to $3.6 million in 2024, then grew by 22.35% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.1 million for Q2 2025, and $3.8 million during Q1 2025.